FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or metastatic HER2-positive breast cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/t-dxd-wins-first-line-indication-her2-breast-cancer-2025a1000zad?src=rss
Author :
Publish date : 2025-12-16 12:34:00
Copyright for syndicated content belongs to the linked Source.
